Moderna’s and Merck’s Personalized mRNA Vaccine Shows Real Promise Against Deadly Skin Cancer Melanoma in Late Stage Trial, Sends Stocks Soaring The news that Moderna and Merck's personalized mRNA vaccine has shown remarkable promise in a Phase 3 trial targeting melanoma is being hailed as a breakthrough moment in cancer treatment.
The therapy uses a sample of a patient's own tumor to teach the immune system to recognize specific mutations and has successfully met its main goals in the trial, sending Moderna's stock soaring over 100% and lifting Merck shares.
Melanoma is one of the deadliest forms of skin cancer, and patients with advanced stages have limited treatment options.